← Back to Screener
Generate Biomedicines, Inc. Common Stock (GENB)
Price$12.12
Favorite Metrics
Price vs S&P 500 (4W)-8.03%
Market Capitalization$1.59B
All Metrics
Price vs S&P 500 (YTD)-5.10%
10-Day Avg Trading Volume0.33M
EPS (Annual)$-1.60
ROI (Annual)-99.89%
ROA (Last FY)-61.52%
Cash Flow / Share (Annual)$-1.61
Net Income / Employee (Annual)$-1
EPS Incl Extra (Annual)$-1.60
Current Ratio (Annual)2.85x
3-Month Avg Trading Volume0.69M
P/S Ratio (Annual)49.59x
Asset Turnover (Annual)0.10x
52-Week High$15.32
EPS Excl Extra (Annual)$-1.60
Quick Ratio (Annual)2.70x
Total Debt / Equity (Annual)0.04x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-696.88%
Cash / Share (Annual)$1.74
ROE (Last FY)-103.57%
EPS Basic Excl Extra (Annual)$-1.60
Revenue / Share (Annual)$0.25
Year-to-Date Return-1.58%
5-Day Price Return-2.73%
EPS Normalized (Annual)$-1.60
Net Profit Margin (Annual)-634.38%
Month-to-Date Return-0.40%
EBITD / Share (Annual)$-1.65
Operating Margin (Annual)-734.38%
Beta1.20x
52-Week Low$11.00
Analyst Recommendations
Apr 2026
4.13
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
GENBGenerate Biomedicines, Inc. Common Stock | — | — | — | — | $12.12 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Generate Biomedicines is a clinical-stage biotechnology company leveraging artificial intelligence and machine learning to design novel protein therapeutics. Its proprietary Generate Platform enables rapid drug discovery and development across multiple therapeutic modalities. The company's pipeline includes three clinical candidates: GB-0895, GB-4362, and GB-5267.